Advertisement

Remnant-like Particle Cholesterol Levels in Patients with Dysbetalipoproteinemia or Coronary Artery Disease

  • Sridevi Devaraj
    Affiliations
    Department of Pathology, the University of Texas Southwestern Medical Center, Dallas, Texas, USA (SD, IJ)
    Search for articles by this author
  • Gloria Vega
    Affiliations
    Department of Internal Medicine, the University of Texas Southwestern Medical Center, Dallas, Texas, USA (RL, SG, IJ)
    Search for articles by this author
  • Rick Lange
    Affiliations
    Center for Human Nutrition (GV, SG, IJ), the University of Texas Southwestern Medical Center, Dallas, Texas, USA
    Search for articles by this author
  • Scott M Grundy
    Affiliations
    Department of Internal Medicine, the University of Texas Southwestern Medical Center, Dallas, Texas, USA (RL, SG, IJ)

    Center for Human Nutrition (GV, SG, IJ), the University of Texas Southwestern Medical Center, Dallas, Texas, USA
    Search for articles by this author
  • Ishwarlal Jialal
    Correspondence
    Requests for reprints should be addressed to I. Jialal, MD, PhD, Department of Internal Medicine and Pathology, University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Blvd., Dallas, Texas 75235-9073
    Affiliations
    Department of Pathology, the University of Texas Southwestern Medical Center, Dallas, Texas, USA (SD, IJ)

    Department of Internal Medicine, the University of Texas Southwestern Medical Center, Dallas, Texas, USA (RL, SG, IJ)

    Center for Human Nutrition (GV, SG, IJ), the University of Texas Southwestern Medical Center, Dallas, Texas, USA
    Search for articles by this author

      Abstract

      Purpose: Several studies have provided support for a pro-atherogenic role for remnant lipoproteins. Thus, the aim of this study was to compare remnant-like particle (RLP) cholesterol levels in patients with coronary artery disease who were normolipidemic with those in controls of similar age and gender. We also assessed the usefulness of measuring RLP-cholesterol levels in patients with type III dyslipidemia.
      Subjects and methods: Remnant-like particle cholesterol levels were measured in 63 normolipidemic men with coronary artery disease and 23 male controls of similar age as well as in 15 patients with type III dyslipidemia and 103 controls, using an immunoaffinity method.
      Results: Remnant-like particle cholesterol levels were significantly increased in men with coronary artery disease compared with controls (7.6 ± 3.8 mg/dL versus 5.7 ± 1.9 mg/dL, P <0.01). In patients with coronary artery disease, RLP-cholesterol levels were correlated with total triglyceride and non–high-density-lipoprotein (HDL) cholesterol levels, but not with HDL-cholesterol levels. RLP-cholesterol levels were significantly elevated in patients with type III dyslipidemia (median 119, range 31 to 240 mg/dL) compared with controls (median 5.6, range 2.2 to 10.5 mg/dL, P <0.001).
      Conclusion: Normolipidemic men with coronary artery disease have increased levels of RLP-cholesterol that is not detected with conventional lipid screening. The RLP-cholesterol assay is a simple method for detecting high concentrations of remnant lipoproteins in patients with type III dyslipidemia.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to The American Journal of Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Havel R.J
        Postprandial hyperlipidemia and RLP.
        Curr Opin Lipidol. 1994; 5: 102-109
        • Stein Y
        • Havel R.J
        Pathophysiology of triglyceride-rich lipoproteins.
        Am J Cardiol. 1991; 68: 8A-10A
        • Kameda K
        • Matsuzawa Y
        • Kubo K
        • et al.
        Increased frequency of lipoprotein disorders similar to type III hyperlipoproteinemia in survivors of myocardial infarction in Japan.
        Atherosclerosis. 1984; 51: 241-249
        • Shimizu H
        • Mori M
        • Saito T
        An increase in serum RLP in NIDDM with microalbuminuria.
        Clin Chim Acta. 1993; 221: 191-196
        • Nestel P.J
        • Fidge N.H
        • Tan M.H
        Increased lipoprotein remnant formation in chronic renal failure.
        NEJM. 1982; 307: 329-333
        • Krauss R.M
        • Lindgren F.T
        • Williams P.T
        • et al.
        IDL and progression of coronary artery disease in hypercholesterolemic men.
        Lancet. 1987; 2: 62-66
        • Knopp R.H
        • Walden C.E
        • Heiss G
        • et al.
        Prevalence and clinical correlates of beta migrating very-low-density lipoproteins. The Lipid Research Clinics Program Prevalence Study.
        Am J Med. 1986; 81: 493-502
        • Tatami R
        • Mabuchi H
        • Ueda K
        • et al.
        IDL and cholesterol-rich very-low-density lipoproteins in angiographically determined coronary artery disease.
        Circulation. 1981; 64: 1174-1183
        • Steiner G
        • Schwartz L
        • Shumak S
        • Poapst M
        The association of increased levels of IDL with smoking and CAD.
        Circulation. 1987; 75: 124-130
        • Krauss R.M
        • Williams P.T
        • Brensike J
        • Detre K.M
        • et al.
        IDL and progression of CAD in hypercholesterolemic men.
        Lancet. 1987; ii: 62-65
        • Gofman J.W
        • Young W
        • Tandy R
        Ischemic heart disease, atherosclerosis and longevity.
        Circulation. 1987; 75: 124-130
        • Nakajima K
        • Okazaki M
        • Taraka A
        • et al.
        Separation and determination of RLP in human serum using monoclonal antibodies to apo B-100 and apo A-1.
        J Clin Ligand Assay. 1996; 19: 177-183
        • Nakajima K
        • Saityo T
        • Tamura A
        • et al.
        Cholesterol in RLP in human serum using monoclonal anti apo B 100 and anti apo A1 immunoaffinity mixed gels.
        Clin Chim Acta. 1993; 223: 53-71
        • Jialal I
        • Hirany S.V
        • Devaraj S
        • Sherwood T.A
        Comparison of an immunoprecipitation method for direct measurement of LDL-C with beta quantification.
        Am J Clin Path. 1995; 104: 76-81
        • Pisani T
        • Gebski C.P
        • Leary E.T
        • et al.
        Accurate direct determination of LDL using an immunoseparation reagent and enzymatic cholesterol assay.
        Arch Pathol Lab Med. 1995; 119: 1127-1135
        • National Cholesterol Education Program
        Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. Summary of the second report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (ATP II).
        JAMA. 1993; 269: 3015-3023
        • Jialal I
        A practical approach to the laboratory diagnosis of dyslipidemia.
        Am J Clin Path. 1996; 106: 128-138
        • Karpe F
        • Steiner G
        • Uffelman K
        • et al.
        Postprandial lipoproteins and progression of coronary atherosclerosis.
        Atherosclerosis. 1994; 106: 83-97
        • Phillips N.R
        • Waters D
        • Havel R.J
        Plasma lipoproteins and progression of CAD evaluated by angiography and clinical events.
        Circulation. 1993; 88: 2762-2770
        • Rapp J.H
        • Lespine A
        • Hamilton R.L
        • et al.
        TG-rich lipoproteins isolated by selected affinity anti-apo B immunosorption from human atherosclerotic plaque.
        Arterioscler Thromb. 1994; 14: 1767-1774
        • Rall S.C
        • Mahley R.W
        The role of Apo E genetic variants in lipoprotein disorders.
        J Intern Med. 1992; 231: 653-659
        • Mahley R.W
        • Innerarity T.L
        • Rall S.C
        • Weisgraber K.H
        Lipoproteins of special significance in atherosclerosis, insights provided by studies of type III hyperlipoproteinemia.
        Ann NY Acad Sci. 1994; 3: 209-221